TAKE THE LEAP
The cost of not paying attention:
diabetic foot complications cost dollars

There is more than one root cause for these diabetic limb complications. To be more effective Podiatrists need to better understand their diabetes patient populations and apply standardized processes, procedures and protocols targeting measured outcomes.

TAKE THE LEAP
Lower extremity
complications in patients with diabetes

Managing, monitoring and measuring outcomes in these populations is critical.

• 25% will experience a diabetic foot ulcer during their lifetime.
• 6% will develop a DFU each year.
• 3.8% who have foot ulcers will have complications leading to an amputation.
• 65% will experience a wound recurrence within 5 years.
• 45% demonstrate mortality within 5 years.

TAKE THE LEAP
Patients don’t think about their feet

Particularly if they have diabetic neuropathy as fewer than 32% of patients with diabetes receive an annual comprehensive diabetic foot examination (CDFE).

TAKE THE LEAP
Why Arche Healthcare

TAKE THE LEAP
You can’t manage
what you can’t measure

TAKE THE LEAP
CLUE®: a health management strategy

CLUE is architected for Payors and other healthcare stakeholders to address the costly complications associated with the lower extremities of patients with diabetes.

CLUE supports both the patient and Podiatrist and is designed to achieve as much as a 54% reduction in the incidence of both foot ulcers and lower extremity amputations. Arche Healthcare’s outcomes measurement methodology has been validated by the (validationinstitute.com).

Arche Healthcare uses proprietary and innovative technology to put the issue in front of the patient, their Podiatrist and their primary care provider (PCP).

OPTYX® is a proprietary cloud-based clinical information system that supports the management and monitoring of lower extremity care in patients with diabetes and measures and reports on their clinical and financial results.

TAKE THE LEAP
Key Features / How It Works

TAKE THE LEAP
InFocus®: a home monitoring solution

InFocus extends the clinical experience into the patient’s home. Educated and engaged by their Arche CDFE, the patient is now equipped and empowered to better care for their feet at home.

The InFocus solution addresses an entire population of people with diabetes providing them with appropriate tools based upon their personalized level of risk for developing a diabetic foot complication.

These tools include the VeriSole mobile app, DermaStat, TempStat and InSight.

TAKE THE LEAP
Traction & Accomplishments

PRODUCT DEVELOPMENT
Arche Healthcare has developed proprietary tools to support the physician in performing the Arche CDFE; a truly Comprehensive Diabetic Foot Experience! Our InFocus® home monitoring strategy supports patient adherence to proven self-care strategies helping reduce the incidence of ulcers and amputations. Arche OPTYX, our patient management system, measures and monitors patient data to identify gaps in care that when realigned with clinical protocols, can create significant reductions in diabetic foot complications.

PATENTS AND TRADEMARKS
We hold patents on PressureStat® TempStat® and are in the process of applying for patents for DermaStat®, InSight® and the Arche OPTYX® system. We hold trademarks for Arche Healthcare®, InFocus®, HealthStep®, One Way to LEAP®, AccuSense®, IRStat®, PressureStat®, TempStat®, InSight®, CLUE® and OPTYX®.

MANUFACTURING AND DISTRIBUTION
DermaStat is manufactured in China. TempStat is manufactured in the US. InSight has a component manufactured in Taiwan and is assembled in the US. We hold the exclusive license for VibraTip® and neuropad® for North America and the Caribbean. PressureStat is manufactured in the Netherlands. All products are distributed through our fulfillment partner in CT.

TAKE THE LEAP
Arche Healthcare Team